University of Dundee

Drug Discovery Unit

Short Code: 
DDU

New Proteomic Study of Trypanosome Cell Cycle

A new study entitled “Proteomic Analysis of the Cell Cycle of Procylic Form Trypanosoma brucei” has just been published in Molecular and Cellular Proteomics (Crozier et al., 2018, Mol Cell Proteomics 2018 17: 1184-1195). This study resulted from a collaboration between the laboratories of Mike Ferguson (BCDD) and Angus Lamond (GRE).  Trypanosoma brucei is an evolutionarily divergent eukaryotic protozoan parasite that causes human and animal trypanosomiasis (also called ‘sleeping sickness’) in sub-Saharan Africa.

DNDi, GlaxoSmithKline, and University of Dundee to identify drug candidates to treat leishmaniasis and Chagas disease

The Drug Discovery Unit (DDU) will collaborate with the not-for-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) and GlaxoSmithKline (GSK) in a bid to discover new pre-clinical drug candidates targeting two parasitic neglected tropical diseases (NTDs), leishmaniasis and Chagas disease.

Congratulations following Promotions for Academic Staff

Kevin Read and Simon Arthur have been promoted to Personal Chair (Professor) as part of the 2017 Annual Review process for academic staff. Kevin Read will become Professor of Quantitative Pharmacology while Simon Arthur will be Professor of Immune Signalling.

“I would like to congratulate both Kevin and Simon on their well-deserved promotions,” said Professor Julian Blow, Dean of Research in the School of Life Sciences. “Both have made significant contributions to their respective fields over a sustained period of time as well as contributing to teaching our undergraduates.”

Biotransformation Expert

We are seeking a personable and enthusiastic individual to take up the post of Biotransformation Expert within the Drug Metabolism and Pharmacokinetics (DMPK) team in the Drug Discovery Unit (DDU), University of Dundee. The DDU has a strong focus to find new drugs to treat diseases of the developing world such as malaria, tuberculosis, visceral leishmaniasis and Chagas disease (see www.drugdiscovery.dundee.ac.uk).

Honorary degree for Professor Mike Ferguson

Professor Mike Ferguson CBE, Regius Professor of Life Sciences and Academic Lead for Research Strategy in the School was awarded a Doctor of Science (DSc) in today’s winter graduation at the University of St. Andrews. Professor Dame Sue Black OBE, Director of the Centre for Anatomy and Human Identification and the Leverhulme Research Centre for Forensic Science was honoured alongside Professor Ferguson. She was awarded an honorary Doctor of Medicine (MD).

Professor Ferguson is photographed with University of St Andrews Principal and Vice-Chancellor Professor Sally Mapstone.

Building understanding of drug entry into gram negative bacterial

There is a very clear need for new antibacterial drug treatments to combat the ever increasing problem of drug resistance. However, one of the major issues with developing new drugs for treating Gram negative bacteria is the challenge of obtaining sufficient levels of compound within the bacteria. This is due to two factors: the lack of permeability of the cell envelope and the presence of efflux pumps which remove compounds from cells.

The aims of the project will be to:

Pages